Work

Use of canakinumab in recurrent gout attacks in patients with multimorbidity — two clinical case reports

Year: 2024

Type: article

Abstract: Gout is a chronic autoinflammatory joint disease affecting an increasing proportion of the population. In treatment of flares we can use traditional anti-inflammatory drugs [nonsteroidal anti-inflammatory drugs (NSAIDs), colchicine and glucocorticoids] and as a second-line biologic therapy with canakinumab which is a selective interleukin-1 beta (IL-1β) antagonist. This paper presents two clinical cases of patients treated with canakinumab due to lack of efficacy and contraindications to first-line drugs.

Source: Rheumatology Forum

DOI: 10.5603/rf.98377

Authors: Anna Panejko, Marta Skoczyńska, Katarzyna Gruszecka

Institutions: Szpital im Tadeusza Marciniaka, Wrocław University of Science and Technology

Language: English

Topic: Gout, Hyperuricemia, Uric Acid

Subfield: Nephrology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W4405923966

FWCI:

Cites:

Cited by:

Related to: 10